Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tuberculosis vaccines in clinical trials.

Literature DB >> 21604985

Tuberculosis vaccines in clinical trials.

Abstract

Effective prophylactic and/or therapeutic vaccination is a key strategy for controlling the global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette-Guérin (BCG), suggests effective vaccination is possible and highlights the need for an improved vaccination strategy. Clinical trials are evaluating both modifications to the existing BCG immunization methods and also novel TB vaccines, designed to replace or boost BCG. Candidate vaccines in clinical development include live mycobacterial vaccines designed to replace BCG, subunit vaccines designed to boost BCG and therapeutic vaccines designed as an adjunct to chemotherapy. There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21604985 PMCID： PMC3409871 DOI： 10.1586/erv.11.28

Source DB: PubMed Journal: Expert Rev Vaccines ISSN： 1476-0584 Impact factor: 5.217

138 in total

1. BCG vaccine. WHO position paper.

Authors:
Journal: Wkly Epidemiol Rec Date: 2004-01-23

2. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.

Authors: Stefan Kostense; Wouter Koudstaal; Mieke Sprangers; Gerrit Jan Weverling; Germaine Penders; Niels Helmus; Ronald Vogels; Margreet Bakker; Ben Berkhout; Menzo Havenga; Jaap Goudsmit
Journal: AIDS Date: 2004-05-21 Impact factor: 4.177

Review 3. BCG vaccination against tuberculosis and leprosy.

Authors: P E Fine
Journal: Br Med Bull Date: 1988-07 Impact factor: 4.291

4. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].

Authors: A Mayr; H Stickl; H K Müller; K Danner; H Singer
Journal: Zentralbl Bakteriol B Date: 1978-12

5. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Authors: Lise Brandt; Yasir A W Skeiky; Mark R Alderson; Yves Lobet; Wilfried Dalemans; Oliver C Turner; Randall J Basaraba; Angelo A Izzo; Todd M Lasco; Philip L Chapman; Steven G Reed; Ian M Orme
Journal: Infect Immun Date: 2004-11 Impact factor: 3.441

6. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies.

Authors: Willem A Hanekom; Jane Hughes; Maushumi Mavinkurve; Megan Mendillo; Marcia Watkins; Hoyam Gamieldien; Sebastian J Gelderbloem; Mzwandile Sidibana; Nazma Mansoor; Virginia Davids; Rose Ann Murray; Anthony Hawkridge; Patrick A J Haslett; Stanley Ress; Gregory D Hussey; Gilla Kaplan
Journal: J Immunol Methods Date: 2004-08 Impact factor: 2.303

7. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein.

Authors: Yasir A W Skeiky; Mark R Alderson; Pamela J Ovendale; Jeffrey A Guderian; Lise Brandt; Davin C Dillon; Antonio Campos-Neto; Yves Lobet; Wilfried Dalemans; Ian M Orme; Steven G Reed
Journal: J Immunol Date: 2004-06-15 Impact factor: 5.422

8. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors: Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal: J Immunol Date: 2004-05-15 Impact factor: 5.422

9. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study.

Authors: Naomi E Aronson; Mathuram Santosham; George W Comstock; Robin S Howard; Lawrence H Moulton; Everett R Rhoades; Lee H Harrison
Journal: JAMA Date: 2004-05-05 Impact factor: 56.272

Review 10. Adenoviruses as vaccine vectors.

Authors: Nia Tatsis; Hildegund C J Ertl
Journal: Mol Ther Date: 2004-10 Impact factor: 11.454

41 in total

Review 1. Vaccination against infection in patients with multiple sclerosis.

Authors: Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal: Nat Rev Neurol Date: 2012-01-24 Impact factor: 42.937

Review 2. Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens.

Authors: Aarti Rana; Shweta Thakur; Girish Kumar; Yusuf Akhter
Journal: Front Genet Date: 2018-11-27 Impact factor: 4.599

3. HIV-1 and the immune response to TB.

Authors: Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal: Future Virol Date: 2013-01 Impact factor: 1.831

4. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Authors: Patricia A Darrah; Diane L Bolton; Andrew A Lackner; Deepak Kaushal; Pyone Pyone Aye; Smriti Mehra; James L Blanchard; Peter J Didier; Chad J Roy; Srinivas S Rao; David A Hokey; Charles A Scanga; Donata R Sizemore; Jerald C Sadoff; Mario Roederer; Robert A Seder
Journal: J Immunol Date: 2014-07-14 Impact factor: 5.422